» Articles » PMID: 22005913

Targets of Anti-endothelial Cell Antibodies in Pulmonary Hypertension and Scleroderma

Overview
Journal Eur Respir J
Specialty Pulmonary Medicine
Date 2011 Oct 19
PMID 22005913
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

Anti-endothelial cell antibodies (AECAs) have been identified in patients with systemic sclerosis (SSc) with and without pulmonary arterial hypertension (PAH) and in patients with idiopathic pulmonary arterial hypertension (iPAH). However, their target antigens remain poorly identified. Sera from 24 patients with SSc without PAH, 20 patients with SSc with PAH, 30 with iPAH and 12 healthy controls were collected. Target antigens were identified by two-dimensional electrophoresis and immunoblotting in protein extracts of human umbilical vein endothelial cells. Targeted antigens were identified by mass spectrometry. Serum immunoglobulin G from patients with SSc with or without PAH and patients with iPAH specifically recognised 110, 82 and 37 protein spots, respectively. Among others, target antigens of AECAs included lamin A/C, tubulin β-chain and vinculin. One-dimension immunoblotting experiments confirmed the identification of lamin A/C and tubulin β-chain. In conclusion, our results confirm the presence of AECA in patients with systemic sclerosis with and without pulmonary arterial hypertension and in those with idiopathic pulmonary arterial hypertension, and provide evidence for the identification of target antigens of these autoantibodies including lamin A/C and tubulin β-chain.

Citing Articles

Inhibition of immunoglobulin E attenuates pulmonary hypertension.

Shu T, Liu Y, Zhou Y, Zhou Z, Li B, Xing Y Nat Cardiovasc Res. 2024; 1(7):665-678.

PMID: 39196237 DOI: 10.1038/s44161-022-00095-9.


Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: From Bedside to Bench and Back Again.

Bahi M, Li C, Wang G, Korman B Int J Mol Sci. 2024; 25(9).

PMID: 38731946 PMC: 11084945. DOI: 10.3390/ijms25094728.


B-cells in pulmonary arterial hypertension: friend, foe or bystander?.

Sanges S, Tian W, Dubucquoi S, Chang J, Collet A, Launay D Eur Respir J. 2024; 63(4).

PMID: 38485150 PMC: 11043614. DOI: 10.1183/13993003.01949-2023.


The Evolving Management and Treatment Options for Patients with Pulmonary Hypertension: Current Evidence and Challenges.

Swisher J, Weaver E Vasc Health Risk Manag. 2023; 19:103-126.

PMID: 36895278 PMC: 9990521. DOI: 10.2147/VHRM.S321025.


Pulmonary adverse events associated with hypertension in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors.

Chen J, Wen Y, Chu X, Liu Y, Su C Front Pharmacol. 2022; 13:944342.

PMID: 36110543 PMC: 9468816. DOI: 10.3389/fphar.2022.944342.